Lilly Finds IMS Data Solution, Uncovers Gemzar Dilution In Kansas City
Executive Summary
Lilly's decision to use IMS Health's wholesale tracking data in the Kansas City area for oncology sales rep bonuses helped lead to the discovery that an area pharmacist appeared to be diluting chemotherapy drugs.
You may also be interested in...
FDA Oversight Of Rx Compounding Should Increase, GAO Study Suggests
Increased FDA oversight of pharmacy compounding may be necessary due to state budgetary constraints, an Oct. 23 General Accounting Office report suggests
FDA Oversight Of Rx Compounding Should Increase, GAO Study Suggests
Increased FDA oversight of pharmacy compounding may be necessary due to state budgetary constraints, an Oct. 23 General Accounting Office report suggests
Lilly, Bristol Drug Dilution Settlement May Increase Focus On “Gray Market”
The size of settlement payments made by Lilly and Bristol-Myers Squibb in the Kansas City drug dilution case is the latest warning to manufacturers that they may need to become more aggressive in policing the so-called "gray market" for pharmaceuticals